---
title: "Barclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265879212.md"
description: "Barclays analyst Etzer Darout maintained a Hold rating on Tvardi Therapeutics with a $5.00 price target. Darout, who covers the Healthcare sector, has an average return of 23.7% and a 54.75% success rate. The general analyst consensus for Tvardi Therapeutics is a Moderate Buy with a $16.00 average price target."
datetime: "2025-11-14T09:06:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265879212.md)
  - [en](https://longbridge.com/en/news/265879212.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265879212.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265879212.md) | [繁體中文](https://longbridge.com/zh-HK/news/265879212.md)


# Barclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)

Barclays analyst Etzer Darout maintained a Hold rating on Tvardi Therapeutics today and set a price target of $5.00.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Darout covers the Healthcare sector, focusing on stocks such as Terns Pharmaceuticals, Exelixis, and Arvinas Holding Company. According to TipRanks, Darout has an average return of 23.7% and a 54.75% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tvardi Therapeutics with a $16.00 average price target.

### Related Stocks

- [Tvardi Therapeutics, Inc. (TVRD.US)](https://longbridge.com/en/quote/TVRD.US.md)

## Related News & Research

- [Tvardi Therapeutics reports larger-than-expected Q4 net loss](https://longbridge.com/en/news/281237072.md)
- [Tvardi Therapeutics Narrows FY25 Loss, Prepares For Key STAT3 Clinical Readouts In 2026](https://longbridge.com/en/news/281358751.md)
- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/en/news/281311983.md)
- [SharonAI Secures Major Long-Term AI Cloud Services Deal](https://longbridge.com/en/news/281363534.md)
- [Meet 'Dobby': The AI agent that could kill the app economy](https://longbridge.com/en/news/281354277.md)